FDA and the International Mail Facilities (IMFs) CD-3, counterfeit detection device. When a product lacks proper labeling, the FDA needs to act quickly to determine if a product should be detained, so a creative approach is needed. To enable faster decisions, the agency employs a variety of tools, including one that can determine if a drug is a counterfeit, one that can determine if a product contains undeclared drugs and another that uses the same technology as airport security to swipe your luggage for explosives. The FDA is actively working on developing an opioid screening method and inte
FDA and the International Mail Facilities (IMFs) CD-3, counterfeit detection device. When a product lacks proper labeling, the FDA needs to act quickly to determine if a product should be detained, so a creative approach is needed. To enable faster decisions, the agency employs a variety of tools, including one that can determine if a drug is a counterfeit, one that can determine if a product contains undeclared drugs and another that uses the same technology as airport security to swipe your luggage for explosives. The FDA is actively working on developing an opioid screening method and intends to initiate a pilot study using this method at the IMFs soon.
Size: 1956px × 1240px
Photo credit: © 2020 Images / Alamy / Afripics
License: Licensed
Model Released: No
Keywords:
